Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo

Wei-Cheng Fang; Sheng-Yiao Lin; Shu-Mei Huang; Cheng-Che E Lan

doi:10.1111/ced.15070

Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo

Clin Exp Dermatol. 2022 Apr;47(4):782-783. doi: 10.1111/ced.15070. Epub 2022 Jan 5.

Authors

Wei-Cheng Fang¹, Sheng-Yiao Lin¹, Shu-Mei Huang^{1

2}, Cheng-Che E Lan^{1

2}

Affiliations

¹ Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
² Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

PMID: 34923664
DOI: 10.1111/ced.15070

Abstract

Combining low-dose tofacitinib with 308-nm excimer may be an effective treatment for patients with nonsegmental vitiligo who were refractory to conventional therapies.

Publication types

Letter

MeSH terms

Humans
Low-Level Light Therapy*
Piperidines
Pyrimidines
Treatment Outcome
Vitiligo* / radiotherapy

Substances

Piperidines
Pyrimidines
tofacitinib

Grants and funding

MOHW109-TDU-B-212-114006 and MOHW110-TDU-B-212-124006/The Ministry of Health and Welfare, Taiwan